Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis U.S. Sales Force Increase Anticipates Up To Five NME Launches

Executive Summary

Novartis is ramping up its U.S. sales force in anticipation of a spate of product launches, the company indicated at its 1999 sales and earnings presentation in London Feb. 17.

You may also be interested in...



Novartis STI 571 Leukemia Trials Heading Toward NDA Filing At End Of 2001

Product registration trials for Novartis' STI 571 for chronic myelogenous leukemia began at the end of 1999, and an NDA filing for the product is planned within the next 18 months.

Novartis STI 571 Leukemia Trials Heading Toward NDA Filing At End Of 2001

Product registration trials for Novartis' STI 571 for chronic myelogenous leukemia began at the end of 1999, and an NDA filing for the product is planned within the next 18 months.

Glaxo Lotronex Studies May Expand Market To Men, Teens, Pediatrics

Glaxo will try to expand the Lotronex (alosetron) market to men, adolescents and children, following the Feb. 9 approval of the irritable bowel syndrome treatment for use in women whose predominant IBS symptom is diarrhea.

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel